• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Doug Kass
    • Bruce Kamich
    • Jim Cramer
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • Trifecta Stocks
  1. Home
  2. / Investing
  3. / Healthcare

Tenet Healthcare: Focus on the Bigger Picture

Sometimes you miss trades or investments if you don't take a step back.
By BRUCE KAMICH
Apr 11, 2018 | 08:43 AM EDT
Stocks quotes in this article: THC

When you look at the movement of stock prices too closely you sometimes miss trades or investments. For example, you need to look at the bigger picture on Tenet Healthcare Corp. (THC) to see the base formation and a pullback as a potential buying opportunity. Join me this morning in looking at Tenet, which was mentioned by Jim Cramer in his "15 Sectors to Buy on a U.S./Chinese Trade War."

In this daily bar chart of THC, below, we can see a strong rally beginning in December. It looks like prices stalled last month and have begun to correct to the downside. Do we liquidate longs from lower levels? Or will this be a pullback within a longer-term move? Continue.

THC is above the rising 50-day moving average line and the 200-day moving average, which started to move higher in late January. The 50-day line crossed above the 200-day line in February for what is commonly called a golden cross. The crossing of these two averages is considered a buy signal by many technical analysts.

The daily On-Balance-Volume (OBV) line was steady from August through November when the price to THC was weak telling us that whatever selling was going on, others found reasons to become buyers. The OBV line turned up in early December signaling that buyers had become aggressive.

The trend-following Moving Average Convergence Divergence (MACD) oscillator moved above the zero line in December for an outright go long signal and is still above the line in bullish territory.

In this weekly bar chart of THC, below, you get the bigger picture. Prices turned down from $60 back in 2015 but they have been bottoming in the $15-$10 area since late 2016. The volume of trading has been heavy around the lows of 2017 signaling a shift in ownership. The weekly OBV line bottomed in April of 2017 and has been on the rise ever since -- a strong sign of new accumulation. The weekly MACD oscillator gave a third cover shorts buy signal this past December and is now in buy territory.

In this Point and Figure chart of THC, below, we can see the base pattern and breakouts at $21 and $22. Prices have reached an upside price target of $22.50 and may need some further consolidation or sideways price action before further gains.

Bottom line: In the short run THC could correct further to the downside, perhaps to fill a gap in the $21-$19 area. THC is likely to stay above the rising 40-week moving average line making, the base pattern bigger and thus able to support a larger rally in the future. Risk below $17.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from trading individual securities.

TAGS: Investing | U.S. Equity | Healthcare

More from Healthcare

UnitedHealth Group Charts Appear Toppy Ahead of Earnings

Bruce Kamich
Jan 19, 2021 8:53 AM EST

The technical indicators of the health benefits concern are not sending strong signals at present.

Moderna Now Looks Like an Effective Long Trade With Few Side Effects

Bruce Kamich
Jan 14, 2021 12:06 PM EST

MRNA has corrected its big November rally and now looks ready to start a fresh advance, according to the charts.

Pacific Biosciences Reaches Our Price Target: Now What?

Bruce Kamich
Jan 13, 2021 12:19 PM EST

Let's check out the charts and technical indicators.

Emergent BioSolutions Is Looking Stronger

Bruce Kamich
Jan 12, 2021 10:37 AM EST

Here's an update on EBS shares.

Danaher Could Trade Higher

Bruce Kamich
Jan 11, 2021 2:50 PM EST

I do not find enough technical reasons to recommend new long positions at this point in time.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 11:38 AM EST CHRIS VERSACE

    Best Stocks to Buy for the Biden Presidency

    President-elect Biden's massive stimulus plan, int...
  • 08:07 AM EST GARY BERMAN

    Wednesday Morning Fibocall for 1/20/2021

    SPX (Long-Term View) The 1/8/21 high @ 3826.69 i...
  • 11:09 AM EST GARY BERMAN

    Is Copper About to Turn to Rust?

    Below is a very long-term copper chart.  As you...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2021 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login